LIK 066

Drug Profile

LIK 066

Alternative Names: LIK066

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure; Obesity; Polycystic ovary syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jan 2018 Novartis completes a phase II trial in Type 2 diabetes mellitus (in patients with decreased renal function and in subjects with normal renal function) in USA (NCT03131479)
  • 27 Oct 2017 Novartis plans a phase II trial for Obesity (In adults, In the elderly) in Japan in December 2017 (NCT03320941)
  • 04 Oct 2017 Novartis initiates enrolment in a phase II trial for Obesity in USA (NCT03205150)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top